Clinical data from independent investigator-initiated studies using [⁶⁸Ga]Ga-PentixaFor demonstrate potential to improve diagnosis in Primary Aldosteronism First-in-human findings with ...
Clinical data from independent investigator-initiated studies using [68Ga]Ga-PentixaFor demonstrate potential to improve diagnosis in Primary AldosteronismFirst-in-human findings with [¹77Lu]Lu-Pentix ...
The Brighterside of News on MSN
Major breakthrough unlocks scalable artificial blood production
In their quest for safe, mass-producible artificial blood, geneticists have long struggled. Our limited knowledge of genetic pathways that govern the development of blood has kept us from producing ...
Exicure Highlights Recent Achievements And Near-Term Strategic Priorities. Burixafor (GPC-100) Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and ...
The CXCR inhibitor market is expanding steadily as interest in targeted oncology and immuno-oncology treatments grows. Rising ...
Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025 Presented preclinical data at EADV 2025 for GS-6791 (NX-0479), a ...
Favorable safety profile enables advancement of radiolabeled PentixaTher to fourth of five planned activity dose levels in investigator-initiated PENTILULA Phase 1/2 trial Milestone marks important ...
Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug Development ...
Barcelona-based Nanoligent, a biotechnology company specialised in the development of targeted nanodrugs for cancer treatment, has secured €12M in a new ...
TipRanks on MSN
Exicure announces near-term strategic priorities
Exicure’s (XCUR) ongoing Phase 2 study is a randomized, open-label, multicenter trial evaluating burixafor, a small molecule CXCR4 antagonist, in ...
New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...
News Medical on MSN
Omega-3 fatty acids regulate mammary gland lipogenesis and development via Gαs-mediated cAMP–EPAC signaling pathway
The research team found that the supplementation of n-3 fatty acids significantly enhances lactation performance even in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback